What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Hematologic Cancers

What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Hematologic Cancers is organized by Research To Practice (RTP) and will be held on Dec 06, 2024 at Manchester Grand Hyatt San Diego, San Diego, California, United States of America.

Description:

What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Chronic Myeloid Leukemia

Learning Objectives
Upon completion of this activity, participants should be able to

• Evaluate factors, including patient age, comorbidities and personal preferences and drug side-effect profile, that contribute to the selection and sequencing of therapies for chronic-phase chronic myeloid leukemia (CML), and offer counsel regarding personalized treatment recommendations.
• Assess the means by which tyrosine kinase inhibitors (TKIs) inhibit CML growth and progression, and understand which TKIs are available to patients with each phase of the disease.
• Review the mechanism of action of and published efficacy and safety data with STAMP (specifically targeting the ABL myristoyl pocket) inhibitors for CML, and appreciate the current role of these agents in the treatment of relapsed/refractory disease.
• Consider the biological rationale for, available and emerging research findings with and potential therapeutic role of STAMP inhibitors as initial treatment for patients with newly diagnosed chronic-phase CML.
• Implement a plan of care to recognize and manage class-effect and agent-specific toxicities associated with agents commonly used for patients with CML in order to support quality of life and continuation of treatment.

Program Schedule — Pacific Time
7:00 AM – 7:30 AM — Registration and Breakfast
7:30 AM – 9:00 AM — Educational Meeting

Discussion Topics
MODULE 1: Up-Front Therapy for Chronic Myeloid Leukemia (CML)
MODULE 2: Management of Relapsed CML, Including Disease with a T315I Mutation
MODULE 3: Tolerability and Other Practical Considerations with Common CML Therapies

Meeting Room
Seaport A-D (Second Level)

What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Chronic Lymphocytic Leukemia

Learning Objectives
Upon completion of this activity, participants should be able to

• Individualize the selection of systemic therapy for patients with newly diagnosed chronic lymphocytic leukemia (CLL), considering new research findings, disease presentation, biomarker profile, coexisting medical conditions, and preference for time-limited or continuous treatment.
• Appraise available Phase III data comparing the efficacy and tolerability of first- and second-generation Bruton tyrosine kinase (BTK) inhibitors, and consider the implications for clinical decision-making for patients with newly diagnosed CLL.
• Appreciate the scientific rationale for the investigation of combined BTK and Bcl-2 inhibition, and review recently presented data documenting the safety and efficacy of this strategy for patients with newly diagnosed CLL.
• Analyze how age, performance status, prior therapeutic exposure and other biological and disease-related factors affect the selection and sequencing of therapy for patients with relapsed/refractory (R/R) CLL.
• Implement a plan of care to recognize and manage side effects and toxicities associated with recently approved and emerging systemic therapies used in the management of CLL.
• Discuss available clinical research demonstrating the efficacy and safety of noncovalent BTK inhibitors for CLL, and use this information to effectively incorporate these agents into the care of patients with R/R disease.
• Evaluate the biological rationale for the investigation of CD19-directed chimeric antigen receptor T-cell therapy for CLL, and identify patients appropriate for this novel therapeutic strategy.
• Recall available and emerging data with novel agents and combination strategies currently under investigation for CLL, and appropriately refer patients for clinical trial participation.

Program Schedule — Pacific Time
7:00 AM – 7:30 AM — Registration and Breakfast
7:30 AM – 9:30 AM — Educational Meeting

Discussion Topics
MODULE 1: Optimizing First-Line Therapy for Chronic Lymphocytic Leukemia (CLL)
MODULE 2: Emerging Role of Bruton Tyrosine Kinase (BTK) Inhibitors in Combination with Bcl-2 Inhibitors
MODULE 3: Optimal Management of Adverse Events with BTK and Bcl-2 Inhibitors; Considerations for Special Patient Populations
MODULE 4: Integration of Noncovalent BTK Inhibitors into the Management of Relapsed/Refractory CLL
MODULE 5: Chimeric Antigen Receptor T-Cell Therapy and Other Novel Strategies for CLL

Meeting Room
Seaport E-H (Second Level)

What Clinicians Want to Know: Addressing Current Questions and Controversies in the Use of CAR T-Cell Therapy and Bispecific Antibodies in the Management of Lymphoma

Learning Objectives
Upon completion of this activity, participants should be able to

• Understand the biological rationale for the development of CD19-directed chimeric antigen receptor (CAR) T-cell therapy as a targeted strategy to eliminate cancer cells in patients with various forms of non-Hodgkin lymphoma (NHL).
• Appraise the scientific justification for the evaluation of CD20 x CD3 bispecific antibodies in patients with various forms of NHL, and assess the similarities and differences among currently available and investigational agents in this class.
• Evaluate the available clinical research with CD19-directed CAR T-cell therapy and CD20 x CD3 bispecific antibodies in the management of relapsed/refractory diffuse large B-cell lymphoma, and optimally incorporate these approaches into current treatment algorithms.
• Assess available research findings with CD19-directed CAR T-cell therapy and CD20 x CD3 bispecific antibodies for other B-cell lymphomas, including follicular lymphoma and mantle cell lymphoma, and identify patients for whom these novel approaches should be considered or recommended.
• Recognize adverse events associated with available and investigational CAR T-cell therapies and bispecific antibodies, and implement strategies to educate patients and manage complications.
• Recall ongoing research attempting to further define the optimal role of CAR T-cell therapy and bispecific antibody-based strategies for NHL, and counsel appropriate patients regarding clinical trial participation.

Program Schedule — Pacific Time
11:00 AM – 11:30 AM — Registration and Lunch
11:30 AM – 1:30 PM — Educational Meeting

Discussion Topics
MODULE 1: Chimeric Antigen Receptor (CAR) T-Cell Therapy for Diffuse Large B-Cell Lymphoma (DLBCL)
MODULE 2: Bispecific Antibody Therapy for DLBCL
MODULE 3: CAR T-Cell Therapy for Other Lymphoma Subtypes
MODULE 4: Bispecific Antibody Therapy for Follicular Lymphoma and Other Lymphoma Subtypes
MODULE 5: Tolerability Considerations with CAR T-Cell and Bispecific Antibody Therapy

Meeting Room
Seaport A-D (Second Level)

What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Myelofibrosis

Learning Objectives
Upon completion of this activity, participants should be able to

• Use an understanding of disease biology and natural history to effectively counsel patients diagnosed with myelofibrosis (MF) regarding their long-term prognosis.
• Analyze how age, performance status, prior therapeutic exposure and other biological and disease-related factors affect the selection and sequencing of therapy for patients with primary and secondary MF.
• Appraise available research findings on the safety and efficacy of approved JAK inhibitors for patients with MF, including those with thrombocytopenia, anemia or compromised renal function.
• Review available research data with and the current clinical role of novel JAK inhibitors for patients with MF and severe thrombocytopenia.
• Evaluate published research findings with JAK inhibitors for patients with MF and anemia to optimize clinical decision-making.
• Assess available research findings with combination regimens incorporating JAK inhibitors and other novel therapies, and consider the potential clinical application.
• Increase participation in active research protocols by counseling appropriately selected patients with MF about the biological rationale for and available efficacy and safety data with novel investigational agents and strategies.

Program Schedule — Pacific Time
11:00 AM – 11:30 AM — Registration and Lunch
11:30 AM – 1:30 PM — Educational Meeting

Discussion Topics
MODULE 1: Current Clinical Decision-Making for Patients with Myelofibrosis (MF) in the Absence of Severe Cytopenias
MODULE 2: Managing MF in Patients with Thrombocytopenia
MODULE 3: Managing MF in Patients with Anemia
MODULE 4: Future Directions in the Management of MF

Meeting Room
Seaport E-H (Second Level)

What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Acute Myeloid Leukemia

Learning Objectives
Upon completion of this activity, participants should be able to

• Recall and apply emerging research data affecting the clinical management of various forms of acute myeloid leukemia (AML).
• Analyze patient-specific factors and available clinical trial data guiding the selection of induction therapy for individuals with primary and secondary AML in order to optimize clinical and quality-of-life outcomes.
• Describe the biological rationale for and available research findings with Bcl-2-targeted therapy for AML, and appraise the current and potential role of this strategy in patient care.
• Reflect on available research with approved FLT3 inhibitors, and use this information to guide disease management for patients with newly diagnosed or progressive AML harboring a FLT3 mutation.
• Understand published data with and the current role of available IDH1/2 inhibitors for patients with newly diagnosed or relapsed/refractory AML and IDH1 or IDH2 mutations, and incorporate these agents into management algorithms.
• Recognize the scientific justification for the development of menin inhibitors for the treatment of certain genetically defined subsets of AML, and consider available research findings with and the potential role of these novel agents.
• Recollect the mechanisms of action of, available data with and ongoing clinical trials evaluating novel agents and approaches for AML, and appropriately counsel patients about the potential benefits of trial participation.

Program Schedule — Pacific Time
2:45 PM – 3:15 PM — Registration and Light Snacks
3:15 PM – 5:15 PM — Educational Meeting

Discussion Topics
MODULE 1: Management of Acute Myeloid Leukemia (AML) in Older Patients
MODULE 2: Selection of Initial Therapy for Younger Patients with AML without a Targetable Mutation, Including Those with Secondary AML
MODULE 3: Role of FLT3 Inhibitors in the Management of AML
MODULE 4: Incorporation of IDH Inhibitors into the Care of Patients with AML
MODULE 5: Potential Role of Menin Inhibitors and Other Novel Agents in the Management of AML

Meeting Room
Seaport A-D (Second Level)

What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Multiple Myeloma

Learning Objectives
Upon completion of this activity, participants should be able to

• Individualize the selection of first-line therapy for patients with newly diagnosed multiple myeloma (MM), considering new clinical research findings, patient- and disease-related factors, including cytogenetic profile, and fitness for stem cell transplantation.
• Appreciate clinical trial data informing the front-line use of monoclonal antibody therapy directed at CD38 for patients with MM eligible or ineligible for stem cell transplant, and effectively identify when and how this strategy should be integrated into disease management.
• Consider published research findings and other clinical factors in the best-practice sequencing of established and novel agents and regimens for patients with relapsed/refractory MM.
• Develop an understanding of the mechanisms of action of and pivotal clinical trial findings with FDA-approved novel therapies to facilitate their integration into MM management algorithms.
• Evaluate the biological rationale for and published research with chimeric antigen receptor (CAR) T-cell therapy directed at B-cell maturation antigen (BCMA) as a targeted strategy for MM, and identify patients for whom this novel approach should be considered or recommended.
• Assess available findings with BCMA- and non-BCMA-directed bispecific antibodies for MM, and recognize patients for whom treatment with or a clinical trial of one of these novel agents would be appropriate.
• Recall the mechanisms of action of and available research data with novel investigational agents and strategies for MM, and appropriately counsel patients about participation in clinical trials.

Program Schedule — Pacific Time
2:45 PM – 3:15 PM — Registration and Light Snacks
3:15 PM – 5:15 PM — Educational Meeting

Discussion Topics
MODULE 1: Management of Newly Diagnosed Multiple Myeloma (MM)
MODULE 2: Integration of Novel Therapies into the Management of Relapsed/Refractory MM
MODULE 3: Chimeric Antigen Receptor T-Cell Therapy for MM
MODULE 4: Bispecific Antibodies in the Treatment of MM
MODULE 5: Other Novel Agents and Strategies Under Investigation for MM

Meeting Room
Seaport E-H (Second Level)